$ARDX + $UNCY could be a smart strategic fit in #CKD hyperphosphatemia. Ardelyx already has commercial infrastructure and a proven sales force targeting nephrologists + large dialysis organizations with XPHOZAH (tenapanor). Unicycive’s OLC is a next-gen lanthanum binder with strong potential for lower pill burden. Preclinical data already shows synergistic phosphate reduction when OLC + tenapanor are used together AND better than either alone. That’s exactly the kind of combo play that could strengthen Ardelyx’s position as they scale XPHOZAH while adding a differentiated binder. With Raab sitting on solid cash (he doesn’t need an ATM whether he knows it or not), growing revenue from IBSRELA + XPHOZAH, and UNCY at a much smaller market cap (~$220M) heading into its June 29 PDUFA, an
View on X ↗